Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders;Étude pilote comparant en aveugle l'effet thérapeutique de deux doses d'agomélatine, agoniste des récepteurs de la mélatonine et antagoniste des récepteurs 5HT2c, chez 30 patients présentant un épisode dépressif majeur

Encephale

Volumn 29, Issue 2, 2003, Pages 165-171

  Loo H ^a   Dalery J ^b   Macher, J P ^c   Payen, A ^d  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b CENTRE HOSPITALIER LE VINATIER   (France)

^c FORENAP   (France)

^d PERCY MILITARY HOSPITAL   (France)

Author keywords

Agomelatine; Inpatients; Major depression; S 20098

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; MELATONIN; PLACEBO; SEROTONIN 2C ANTAGONIST; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; SEROTONIN RECEPTOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; FOLLOW UP; HEADACHE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MYALGIA; NAUSEA; OUTPATIENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOMNOLENCE; VERTIGO; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; MALE;

ACETAMIDES; ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; PILOT PROJECTS; RECEPTORS, SEROTONIN;

EID: 0038707200     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and Statistical Manual of Mental Disorders, third edition revised. Washington, DC: American Psychiatric Association, 1987.
2. ARBEITSGEMEINSCHAFT FÜR METHODIK UND DOKUMENTATION IN DER PSYCHIATRIE. Das AMDP-System. Manual zur Dokumentation Psychiatrischer Befunde. Berlin: Springer-Verlag, 1979.
3. ANDERSON IM, TOMENSON BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacology 1994; 8 (4): 238-49.
4. ANGST J. How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, eds. Long-term treatment of depression. Chichester: Wiley, 1992; 1-13.
5. ARMSTRONG SM, McNULTY OM, GUARDIOLA-LEMAÎTRE B et al. Successful use of S-20098 and melatonin in an animal model of delayed sleep-phase syndrome. Pharmacol Biochem Behav 1993; 46: 45-9.
6. BELSHER G, COSTELLO CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988; 104: 84-96.
7. BERTSCHY G, VANDEL S. Les liens entre suicide et dépression. Aspects épidémiologiques. Encephale 1991; 17: 33-6.
8. 2 receptors by CRE-luciferase reporter assay. Eur J Pharmacol 2000; 390: 15-24.
9. DUAG (Danish University Antidepressant Group). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-99.
10. DUNBAR GC, COHN JB, FABRE LF et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991; 159: 394-8.
11. DUNNER DL. New strategies for improving the treatment of depression. J Clin Psychiatry 2000; 61 (Suppl 11): 3.
12. GUY W, ECDU. Assessment Manual for Psychopharmacology. National Institute of Mental Health (ed.), 1976.
13. HAMILTON M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96.
14. HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
15. HISCHFELD RM, KELLER MB, PARNICO S et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. J Am Med Assoc 1997; 277: 333-40.
16. KELLER MB. The long-term treatment of depression. J Clin Psychiatry 1999; 60 (Suppl. 17): 41-5.
17. LE PAPE A, LECOMTE T. Aspects socio-économiques de la dépression. Evolution 1980-81/1991-92. CREDES, juin 1996: 1128.
18. LEPINE JP, GASTPAR J, MENDLEWICZ J et al. Depression in the community: the first pan - European study DEPRES (Depression Research, in European Society). Intern Clin Psychopharmacol 1997; 12: 19-29.
19. MARTINET L, GUARDIOLA-LEMAÎTRE B, MOCAËR E. Entrainment of circadian rhythms by S-20098 a melatonin agonist is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996; 54 (4): 713-8.
20. MONTEJO AL, LLORCA G, IZQUIERDO JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective study of 1022 outpatients. J Clin Psychiatry 2001; 62 (Suppl 3): 10-21.
21. MONTGOMERY SA. Clinically relevance effect sizes in depression. Eur Neuropsychopharmacol 1994; 4(3): 283-4.
22. MONTGOMERY SA, ÅSBERG M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 72: 239-45.
23. PAYKEL ES. Remission and residual symptomatology in major depression. Psychopathology 1998; 31: 5-14.
24. REDMAN JR, GUARDIOLA-LEMAÎTRE B, BROWN M et al. Dosedependent effects of S-20098, a melatonin agonist on direction of reentrainment of rat circadian rhythms. Psychopharmacology 1995; 118: 385-90.
25. ROSENBAUM J, FAVA M, HOOG SL et al. Reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87.
26. ROST K, ZHANG M, FORTNEY J et al. Persistently poor outcomes of undetected major depression in primary care. Gen Hosp Psychiatry 1998; 20: 12-20.
27. VAN REETH O, OLIVARES Y, ZHANG FW et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 1997; 762 (1-2): 185-94.
28. VAN REETH O, OLIVARES E, TUREK FW et al. Resynchronisation of a diumal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 1998; 9: 1901-5.
29. VAN REETH O, WEIBEL L., OLIVARES E et al. Melatonin or a melatonin agonist correct age-related changes in circadian response to an environmental stimulus. Am J Physiol 2001; 280: 1582-91.
30. WEIBEL L, TUREK FW, MOCAËR E et al. A melatonin agonist facilitates circadian clock resynchronisation in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000; 880 (1-2): 207-11.
31. WELLS KB, GLODING JM, BURNHAM MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 1988; 245: 976-81.
32. WEISSMAN MM, BLANC RC, CAMINO GJ et al. Cross-national epidemiology of major depression and bipolar disorder. J Am Med Assoc 1996; 276: 293-9.
33. YING SW, RUSAK B, DELAGRANGE P et al. Melatonin analogues as agonist and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996; 296: 33-42.